Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights novel treatment options for alopecia areata, focusing on nanoparticulate drug-delivery systems to improve the effectiveness and targeting of therapies for this complex autoimmune condition.

This study found that in mice with alopecia areata, CD8+ T cells showed clonal expansion and specific regulatory networks, which might help identify new therapeutic targets for patients not responding to JAK inhibitors.

This study identified that while the overall burden of AA among adolescents and young adults globally continues to rise, the age-standardized rates have slightly decreased, with notable disparities across age, gender, region, and socioeconomic status.

Genetic testing for hairless gene mutations is crucial to correctly diagnose and treat atrichia with papular lesions.

This study in Al-Taif, KSA, observed a higher-than-expected prevalence of alopecia areata, predominantly linked to autoimmune causes, with topical corticosteroids and systemic vitamins identified as the most effective treatment.

This case report describes the first known recovery from alopecia universalis using standard immunosuppression after lung transplantation in a patient with advanced bronchiectasis.

This study found that the presence of CD3(+) T-cells within empty follicular fibrous tracts is a reliable indicator for diagnosing diffuse alopecia areata instead of pattern hair loss.

This study reported an increase in allergic contact dermatitis cases linked to natural products, particularly propolis and marigold, with a higher incidence in women than men.

This study found that high-frequency ultrasonography may effectively distinguish different stages of alopecia areata and differentiate it from other scalp conditions.

Azathioprine treatment led to rapid hair regrowth in a woman with alopecia universalis.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

In this study, platelet-rich plasma treatment showed minimal effectiveness for Alopecia Areata but was more effective than no treatment, with a 20% improvement observed compared to 3.3% in the control group.

This abstract contains subscription and access information for Wolters Kluwer Health journals but reports no research findings.

In this study, researchers observed vitamin D insufficiency in many patients with Alopecia Areata, suggesting its potential role in managing this autoimmune condition.

This article reviews the causes and current treatment options for androgenetic alopecia, reporting no new clinical findings and highlighting the need for more therapeutic choices.

This case study describes a man with long-standing alopecia universalis who experienced hair regrowth after taking testosterone, chorionic gonadotropin, and DHEA-S.

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

In this study, researchers found that azathioprine significantly improved hair regrowth in patients with moderate to severe alopecia areata over 10 years, with hair loss decreasing from 74.2% to 5.2% and demonstrating long-term safety and efficacy.

This case study highlights a patient with alopecia areata who also has eosinophilic esophagitis, suggesting it may be considered an atopic disease and a potential trigger for alopecia areata in affected patients.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study found that among Chinese patients with alopecia areata, those with alopecia totalis/universalis had an earlier onset, longer duration, and more severe quality of life impact compared to those with patchy alopecia.

This retrospective study concluded that alopecia areata in elderly patients showed mild severity and a favorable treatment response, with no link found between hair graying and the extent of hair loss.

This case report describes successful hair regrowth and repigmentation in a patient with scalp-localized alopecia areata following treatment with Sunetics Laser therapy.

This review discusses the psychological and economic impact of alopecia areata in Asia, highlighting significant quality of life reductions and a substantial financial burden on patients without providing new clinical results.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.